Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published September 1, 2001 Previous issue | Next issue

  • Volume 108, Issue 5
Go to section:
  • In this issue
  • Spotlight
  • Perspectives
  • Commentaries
  • Research Articles
In this issue
In This Issue
John Ashkenas
John Ashkenas
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):639-639. https://doi.org/10.1172/JCI119933.
View: Text | PDF

In This Issue

  • Text
  • PDF
Abstract

Authors

John Ashkenas

×
Spotlight
The experimental use of antisense oligonucleotides: a guide for the perplexed
C.A. Stein
C.A. Stein
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):641-644. https://doi.org/10.1172/JCI13885.
View: Text | PDF

The experimental use of antisense oligonucleotides: a guide for the perplexed

  • Text
  • PDF
Abstract

Authors

C.A. Stein

×
Perspectives
Series Introduction: Multiligand receptors and human disease
Monty Krieger, David M. Stern
Monty Krieger, David M. Stern
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):645-647. https://doi.org/10.1172/JCI13932.
View: Text | PDF

Series Introduction: Multiligand receptors and human disease

  • Text
  • PDF
Abstract

Authors

Monty Krieger, David M. Stern

×

Is the class A macrophage scavenger receptor (SR-A) multifunctional? — The mouse’s tale
Nick Platt, Siamon Gordon
Nick Platt, Siamon Gordon
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):649-654. https://doi.org/10.1172/JCI13903.
View: Text | PDF

Is the class A macrophage scavenger receptor (SR-A) multifunctional? — The mouse’s tale

  • Text
  • PDF
Abstract

Authors

Nick Platt, Siamon Gordon

×
Commentaries
Turning down insulin signaling
Morris J. Birnbaum
Morris J. Birnbaum
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):655-659. https://doi.org/10.1172/JCI13714.
View: Text | PDF

Turning down insulin signaling

  • Text
  • PDF
Abstract

Authors

Morris J. Birnbaum

×

Peripheral prion pursuit
Adriano Aguzzi
Adriano Aguzzi
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):661-662. https://doi.org/10.1172/JCI13919.
View: Text | PDF

Peripheral prion pursuit

  • Text
  • PDF
Abstract

Authors

Adriano Aguzzi

×

An experiment of nature: genetic l-arginine deficiency and NO insufficiency
Joseph Loscalzo
Joseph Loscalzo
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):663-664. https://doi.org/10.1172/JCI13848.
View: Text | PDF

An experiment of nature: genetic l-arginine deficiency and NO insufficiency

  • Text
  • PDF
Abstract

Authors

Joseph Loscalzo

×

An alternative lifestyle for immortalized oral keratinocytes
Roger R. Reddel
Roger R. Reddel
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):665-667. https://doi.org/10.1172/JCI13818.
View: Text | PDF

An alternative lifestyle for immortalized oral keratinocytes

  • Text
  • PDF
Abstract

Authors

Roger R. Reddel

×
Research Articles
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
Wen-Fang Cheng, … , Morris Ling, T.-C. Wu
Wen-Fang Cheng, … , Morris Ling, T.-C. Wu
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):669-678. https://doi.org/10.1172/JCI12346.
View: Text | PDF

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen

  • Text
  • PDF
Abstract

Antigen-specific cancer immunotherapy and antiangiogenesis have emerged as two attractive strategies for cancer treatment. An innovative approach that combines both mechanisms will likely generate the most potent antitumor effect. We tested this approach using calreticulin (CRT), which has demonstrated the ability to enhance MHC class I presentation and exhibit an antiangiogenic effect. We explored the linkage of CRT to a model tumor antigen, human papilloma virus type-16 (HPV-16) E7, for the development of a DNA vaccine. We found that C57BL/6 mice vaccinated intradermally with CRT/E7 DNA exhibited a dramatic increase in E7-specific CD8+ T cell precursors and an impressive antitumor effect against E7-expressing tumors compared with mice vaccinated with wild-type E7 DNA or CRT DNA. Vaccination of CD4/CD8 double-depleted C57BL/6 mice and immunocompromised (BALB/c nu/nu) mice with CRT/E7 DNA or CRT DNA generated significant reduction of lung tumor nodules compared with wild-type E7 DNA, suggesting that antiangiogenesis may have contributed to the antitumor effect. Examination of microvessel density in lung tumor nodules and an in vivo angiogenesis assay further confirmed the antiangiogenic effect generated by CRT/E7 and CRT. Thus, cancer therapy using CRT linked to a tumor antigen holds promise for treating tumors by combining antigen-specific immunotherapy and antiangiogenesis.

Authors

Wen-Fang Cheng, Chien-Fu Hung, Chee-Yin Chai, Keng-Fu Hsu, Liangmei He, Morris Ling, T.-C. Wu

×

Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection
Christopher A. Haskell, … , James B. Rottman, Israel F. Charo
Christopher A. Haskell, … , James B. Rottman, Israel F. Charo
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):679-688. https://doi.org/10.1172/JCI12976.
View: Text | PDF

Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection

  • Text
  • PDF
Abstract

Fractalkine (Fk) is a structurally unusual member of the chemokine family. To determine its role in vivo, we generated mice with a targeted disruption of CX3CR1, the receptor for Fk. CX3CR1–/– mice were phenotypically indistinguishable from wild-type mice in a pathogen-free environment. In response to antibody-induced glomerulonephritis, CX3CR1–/– and CX3CR1+/+ mice had similar levels of proteinuria and injury. CX3CR1–/– and CX3CR1+/+ mice also developed similar levels of disease in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. We performed heterotopic MHC class I/II cardiac transplants from BALB/c mice into C57BL/6 mice. In the absence of cyclosporin A (CsA), there was no difference in graft survival time between CX3CR1–/– and CX3CR1+/+ recipient mice. However, in the presence of subtherapeutic levels of CsA, graft survival time was significantly increased in the CX3CR1–/– mice. Characterization of cells infiltrating the grafts revealed a selective reduction in natural killer cells in the CX3CR1–/– recipients in the absence of CsA and a reduction in macrophages, natural killer cells, and other leukocytes in the presence of CsA. We conclude that Fk plays an important role in graft rejection. The development of CX3CR1 antagonists may allow reductions in the doses of immunosuppressive drugs used in transplantation.

Authors

Christopher A. Haskell, Wayne W. Hancock, David J. Salant, Wei Gao, Vilmos Csizmadia, Wendy Peters, Kerrie Faia, Omar Fituri, James B. Rottman, Israel F. Charo

×

Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement
Joe G.N. Garcia, … , James R. Bamberg, Denis English
Joe G.N. Garcia, … , James R. Bamberg, Denis English
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):689-701. https://doi.org/10.1172/JCI12450.
View: Text | PDF

Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement

  • Text
  • PDF
Abstract

Substances released by platelets during blood clotting are essential participants in events that link hemostasis and angiogenesis and ensure adequate wound healing and tissue injury repair. We assessed the participation of sphingosine 1-phosphate (Sph-1-P), a biologically active phosphorylated lipid growth factor released from activated platelets, in the regulation of endothelial monolayer barrier integrity, which is key to both angiogenesis and vascular homeostasis. Sph-1-P produced rapid, sustained, and dose-dependent increases in transmonolayer electrical resistance (TER) across both human and bovine pulmonary artery and lung microvascular endothelial cells. This substance also reversed barrier dysfunction elicited by the edemagenic agent thrombin. Sph-1-P–mediated barrier enhancement was dependent upon Giα-receptor coupling to specific members of the endothelial differentiation gene (Edg) family of receptors (Edg-1 and Edg-3), Rho kinase and tyrosine kinase-dependent activation, and actin filament rearrangement. Sph-1-P–enhanced TER occurred in conjunction with Rac GTPase- and p21-associated kinase–dependent endothelial cortical actin assembly with recruitment of the actin filament regulatory protein, cofilin. Platelet-released Sph-1-P, linked to Rac- and Rho-dependent cytoskeletal rearrangement, may act late in angiogenesis to stabilize newly formed vessels, which often display abnormally increased vascular permeability.

Authors

Joe G.N. Garcia, Feng Liu, Alexander D. Verin, Anna Birukova, Melissa A. Dechert, William T. Gerthoffer, James R. Bamberg, Denis English

×

Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie
Pierre Aucouturier, … , Richard I. Carp, Thomas Wisniewski
Pierre Aucouturier, … , Richard I. Carp, Thomas Wisniewski
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):703-708. https://doi.org/10.1172/JCI13155.
View: Text | PDF

Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie

  • Text
  • PDF
Abstract

Transmissible spongiform encephalopathies display long incubation periods at the beginning of which the titer of infectious agents (prions) increases in peripheral lymphoid organs. This “replication” leads to a progressive invasion of the CNS. Follicular dendritic cells appear to support prion replication in lymphoid follicles. However, the subsequent steps of neuroinvasion remain obscure. CD11c+ dendritic cells, an unrelated cell type, are candidate vectors for prion propagation. We found a high infectivity titer in splenic dendritic cells from prion-infected mice, suggesting that dendritic cells carry infection. To test this hypothesis, we injected RAG-10/0 mice intravenously with live spleen cell subsets from scrapie-infected donors. Injection of infected dendritic cells induced scrapie without accumulation of prions in the spleen. These results suggest that CD11c+ dendritic cells can propagate prions from the periphery to the CNS in the absence of any additional lymphoid element.

Authors

Pierre Aucouturier, Frédéric Geissmann, Diane Damotte, Gabriela P. Saborio, Harry C. Meeker, Regina Kascsak, Richard Kascsak, Richard I. Carp, Thomas Wisniewski

×

Quantitative effects of Nf1 inactivation on in vivo hematopoiesis
Youyan Zhang, … , Kevin Shannon, D. Wade Clapp
Youyan Zhang, … , Kevin Shannon, D. Wade Clapp
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):709-715. https://doi.org/10.1172/JCI12758.
View: Text | PDF

Quantitative effects of Nf1 inactivation on in vivo hematopoiesis

  • Text
  • PDF
Abstract

The NF1 tumor-suppressor gene is frequently inactivated in juvenile myelomonocytic leukemia, and Nf1 mutant mice model this myeloproliferative disorder (MPD). Competitive repopulation assays were performed to quantify the proliferative advantage of Nf1–/– hematopoietic cells in vivo. Nf1 mutant stem cells demonstrated a growth advantage that was greatest in myeloid lineage cells and least pronounced in T lymphocytes. Surprisingly, although low numbers of Nf1-deficient cells consistently outcompeted wild-type cells, levels of chimerism were stable over months of observation, and MPD was not observed unless threshold numbers of mutant cells were injected. These data showing that normal competitor cells can strongly modulate the growth of mutant populations in vivo have general implications for modeling cancer in the mouse. In particular, strains in which cancer-associated mutations are expressed in fields of target cells may not accurately model early events in tumorigenesis because they eliminate the requirement for a mutant clone to outcompete resident normal cells.

Authors

Youyan Zhang, Brigit R. Taylor, Kevin Shannon, D. Wade Clapp

×

Vascular endothelial dysfunction resulting from l-arginine deficiency in a patient with lysinuric protein intolerance
Yoshihiro Kamada, … , Sumio Kawata, Yuji Matsuzawa
Yoshihiro Kamada, … , Sumio Kawata, Yuji Matsuzawa
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):717-724. https://doi.org/10.1172/JCI11260.
View: Text | PDF

Vascular endothelial dysfunction resulting from l-arginine deficiency in a patient with lysinuric protein intolerance

  • Text
  • PDF
Abstract

Although L-arginine is the only substrate for nitric oxide (NO) production, no studies have yet been reported on the effect of an L-arginine deficiency on vascular function in humans. Lysinuric protein intolerance (LPI) is a rare autosomal recessive defect of dibasic amino acid transport caused by mutations in the SLC7A7 gene, resulting in an L-arginine deficiency. Vascular endothelial function was examined in an LPI patient who was shown to be a compound heterozygote for two mutations in the gene (5.3-kbp Alu-mediated deletion, IVS3+1G→Α). The lumen diameter of the brachial artery was measured in this patient and in healthy controls at rest, during reactive hyperemia (endothelium-dependent vasodilation [EDV]), and after sublingual nitroglycerin administration (endothelium-independent vasodilation [EIV]) using ultrasonography. Both EDV and NOx concentrations were markedly reduced in the patient compared with those for the controls. They became normal after an L-arginine infusion. EIV was not significantly different between the patient and controls. Positron emission tomography of the heart and a treadmill test revealed ischemic changes in the patient, which were improved by the L-arginine infusion. Thus, in the LPI patient, L-arginine deficiency caused vascular endothelial dysfunction via a decrease in NO production.

Authors

Yoshihiro Kamada, Hiroyuki Nagaretani, Shinji Tamura, Tohru Ohama, Takao Maruyama, Hisatoyo Hiraoka, Shizuya Yamashita, Akira Yamada, Shinichi Kiso, Yoshiaki Inui, Nobuyuki Ito, Yoshiro Kayanoki, Sumio Kawata, Yuji Matsuzawa

×

Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism
Oliver G. Opitz, … , Hubert E. Blum, Anil K. Rustgi
Oliver G. Opitz, … , Hubert E. Blum, Anil K. Rustgi
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):725-732. https://doi.org/10.1172/JCI11909.
View: Text | PDF

Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism

  • Text
  • PDF
Abstract

The immortalization of human cells is a critical step in multistep carcinogenesis. Oral-esophageal carcinomas, a model system to investigate molecular mechanisms underlying squamous carcinogenesis, frequently involve cyclin D1 overexpression and inactivation of the p53 tumor suppressor. Therefore, our goal was to establish the functional role of cyclin D1 overexpression and p53 inactivation in the immortalization of primary human oral squamous epithelial cells (keratinocytes) as an important step toward malignant transformation. Cyclin D1 overexpression alone was found to induce extension of the replicative life span of normal oral keratinocytes, whereas the combination of cyclin D1 overexpression and p53 inactivation led to their immortalization. This study also demonstrates that immortalization of oral keratinocytes can be independent of telomerase activation, involving an alternative pathway of telomere maintenance (ALT).

Authors

Oliver G. Opitz, Yasir Suliman, William C. Hahn, Hideki Harada, Hubert E. Blum, Anil K. Rustgi

×

Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle
Vincent Lebon, … , Douglas L. Rothman, Gerald I. Shulman
Vincent Lebon, … , Douglas L. Rothman, Gerald I. Shulman
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):733-737. https://doi.org/10.1172/JCI11775.
View: Text | PDF

Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle

  • Text
  • PDF
Abstract

The mechanism underlying the regulation of basal metabolic rate by thyroid hormone remains unclear. Although it has been suggested that thyroid hormone might uncouple substrate oxidation from ATP synthesis, there are no data from studies on humans to support this hypothesis. To examine this possibility, we used a novel combined 13C/31P nuclear magnetic resonance (NMR) approach to assess mitochondrial energy coupling in skeletal muscle of seven healthy adults before and after three days of triiodothyronine (T3) treatment. Rates of ATP synthesis and tricarboxylic acid (TCA) cycle fluxes were measured by 31P and 13C NMR spectroscopy, respectively, and mitochondrial energy coupling was assessed as the ratio. Muscle TCA cycle flux increased by approximately 70% following T3 treatment. In contrast, the rate of ATP synthesis remained unchanged. Given the disproportionate increase in TCA cycle flux compared with ATP synthesis, these data suggest that T3 promotes increased thermogenesis in part by promoting mitochondrial energy uncoupling in skeletal muscle.

Authors

Vincent Lebon, Sylvie Dufour, Kitt Falk Petersen, Jianming Ren, Beat M. Jucker, Lori A. Slezak, Gary W. Cline, Douglas L. Rothman, Gerald I. Shulman

×

Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis
Tanuja Chitnis, … , Mohamed H. Sayegh, Samia J. Khoury
Tanuja Chitnis, … , Mohamed H. Sayegh, Samia J. Khoury
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):739-747. https://doi.org/10.1172/JCI12563.
View: Text | PDF

Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis

  • Text
  • PDF
Abstract

Experimental autoimmune encephalomyelitis (EAE) is mediated by myelin-specific CD4+ T cells secreting Th1 cytokines, while recovery from disease is associated with expression of Th2 cytokines. Investigations into the role of individual cytokines in disease induction have yielded contradictory results. Here we used animals with targeted deletion of the STAT4 or STAT6 genes to determine the role of these signaling molecules in EAE. The STAT4 pathway controls the differentiation of cells into a Th1 phenotype, while the STAT6 pathway controls the differentiation of cells into a Th2 phenotype. We found that mice deficient in STAT4 are resistant to the induction of EAE, with minimal inflammatory infiltrates in the central nervous system. In contrast, STAT6-deficient mice, which have a predominantly Th1 phenotype, experience a more severe clinical course of EAE as compared with wild-type or STAT4 knockout mice. In addition, adoptive transfer studies confirm the regulatory functions of a Th2 environment in vivo. These novel data indicate that STAT4 and STAT6 genes play a critical role in regulating the autoimmune response in EAE.

Authors

Tanuja Chitnis, Nader Najafian, Christina Benou, Alan D. Salama, Michael J. Grusby, Mohamed H. Sayegh, Samia J. Khoury

×

5-hydroxytryptamine strongly inhibits fluid secretion in guinea pig pancreatic duct cells
Atsushi Suzuki, … , Hiroyuki Hamada, Tetsuo Hayakawa
Atsushi Suzuki, … , Hiroyuki Hamada, Tetsuo Hayakawa
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):749-756. https://doi.org/10.1172/JCI12312.
View: Text | PDF

5-hydroxytryptamine strongly inhibits fluid secretion in guinea pig pancreatic duct cells

  • Text
  • PDF
Abstract

We studied the distribution of 5-hydroxytryptamine– (5-HT-) containing cells in the guinea pig pancreas and examined the effects of 5-HT on fluid secretion by interlobular pancreatic ducts. The 5-HT–immunoreactive cells with morphological characteristics of enterochromaffin (EC) cells were scattered throughout the duct system and were enriched in islets of Langerhans. The fluid secretory rate in the isolated interlobular ducts was measured by videomicroscopy. Basolateral applications of 5-HT strongly but reversibly reduced HCO3-dependent, as well as secretin- and acetylcholine- (ACh-) stimulated, fluid secretion, whereas 5-HT applied into the lumen had no such effects. Secretin-stimulated fluid secretion could be inhibited by a 5-HT3 receptor agonist, but not by agonists of the 5-HT1, 5-HT2, or 5-HT4 receptors. Under the stimulation with secretin, 5-HT decreased the intracellular pH (pHi) and reduced the rate of pHi recovery after acid loading with NH4+, suggesting that 5-HT inhibits the intracellular accumulation of HCO3–. The elevation of intraductal pressure in vivo reduced secretin-stimulated fluid secretion, an effect that could be attenuated by a 5-HT3 receptor antagonist. Thus, 5-HT, acting through basolateral 5-HT3 receptors, strongly inhibits spontaneous, secretin-, and ACh-stimulated fluid secretion by guinea pig pancreatic ducts. 5-HT released from pancreatic ductal EC cells on elevation of the intraductal pressure may regulate fluid secretion of neighboring duct cells in a paracrine fashion.

Authors

Atsushi Suzuki, Satoru Naruse, Motoji Kitagawa, Hiroshi Ishiguro, Toshiyuki Yoshikawa, Shigeru B.H. Ko, Akiko Yamamoto, Hiroyuki Hamada, Tetsuo Hayakawa

×

HIV-1 infection impairs cell cycle progression of CD4+ T cells without affecting early activation responses
Scott F. Sieg, … , Clifford V. Harding, Michael M. Lederman
Scott F. Sieg, … , Clifford V. Harding, Michael M. Lederman
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):757-764. https://doi.org/10.1172/JCI12685.
View: Text | PDF

HIV-1 infection impairs cell cycle progression of CD4+ T cells without affecting early activation responses

  • Text
  • PDF
Abstract

Failure of CD4+ T cells to proliferate in response to antigenic stimulation is a characteristic of HIV infection. Analysis of the proliferation defect has been hampered by an inability to identify CD4+ cells with T cell receptor specificity for antigen. To focus only on cells that had been stimulated through the T cell receptor, CD4+ T cells were stimulated with an anti-Vβ3 Ab that activates approximately 3–5% of peripheral blood T cells. This approach revealed proliferation defects in cells from HIV-infected patients that were not appreciated using anti-CD3 Ab stimulation and provided the capacity to examine responses on a single cell basis. After anti-Vβ3 Ab stimulation, CD4+Vβ3+ cells from HIV-infected patients demonstrated defects in expression of cell cycle–associated proteins, D-type cyclins, and cyclin A. However, the expression of early activation markers, CD69 and CD25, was not significantly impaired in cells from most patients. Thus, CD4+ T cell proliferation failure in HIV disease is characterized by dysregulated activation that precludes cell cycle progression. This proliferation defect was most apparent in patients with diminished CD4+ T cell numbers and higher plasma HIV RNA levels. CD4+ T cell proliferation failure may be a key determinant of immune impairment in HIV disease.

Authors

Scott F. Sieg, Clifford V. Harding, Michael M. Lederman

×

Limited heterogeneity of T cell receptor BV usage in aplastic anemia
Weihua Zeng, … , Guibin Chen, Neal S. Young
Weihua Zeng, … , Guibin Chen, Neal S. Young
Published September 1, 2001
Citation Information: J Clin Invest. 2001;108(5):765-773. https://doi.org/10.1172/JCI12687.
View: Text | PDF

Limited heterogeneity of T cell receptor BV usage in aplastic anemia

  • Text
  • PDF
Abstract

Immune mediation of aplastic anemia (AA) has been inferred from clinical responsiveness to immunosuppressive therapies and a large body of circumstantial laboratory evidence. However, neither the immune response nor the nature of the antigens recognized has been well characterized. We established a large number of CD4 and CD8 T cell clones from a patient with AA and analyzed their T cell receptor (TCR) usage. Most CD4 clones displayed BV5, whereas most CD8 clones displayed BV13. We found sequence identity for complementarity determining region 3 (CDR3) among a majority of CD4 clones; the same sequence was present in marrow lymphocytes from four other patients with AA but was not detected in controls. The dominant CD4 clone showed a Th1 secretion pattern, lysed autologous CD34 cells, and inhibited their hematopoietic colony formation. In three of four patients, successful immunosuppressive treatment led to marked decrease in clones bearing the dominant CDR3 BV5 sequence. These results suggest surprisingly limited heterogeneity of the T cell repertoire in an individual patient and similarity at the molecular level of the likely pathological lymphocyte response among multiple patients with AA, consistent with recognition of limited numbers of antigens shared by individuals with the same HLA type in this disease.

Authors

Weihua Zeng, Jaroslaw P. Maciejewski, Guibin Chen, Neal S. Young

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts